Literature DB >> 21769851

Fine mapping of a major histocompatibility complex in ankylosing spondylitis: association of the HLA-DPA1 and HLA-DPB1 regions.

Roberto Díaz-Peña1, Ana M Aransay, Jacome Bruges-Armas, Antonio López-Vázquez, Naiara Rodríguez-Ezpeleta, Iñaki Mendibil, Alejandra Sánchez, Juan Carlos Torre-Alonso, Bruno F Bettencourt, Juan Mulero, Eduardo Collantes, Carlos López-Larrea.   

Abstract

OBJECTIVE: To investigate the potential association of major histocompatibility complex (MHC) markers other than HLA-B27 with ankylosing spondylitis (AS).
METHODS: A total of 603 patients with AS and 542 healthy control subjects, all of whom were HLA-B27 positive, were selected for this study based on clinical criteria. First, high-density genotyping across the MHC region (2,360 single-nucleotide polymorphisms [SNPs]) was performed in a cohort of 191 patients and 241 control subjects. After a fine-mapping study, 5 SNPs from the HLA-DPA1/DPB1 region were validated in a second cohort of 412 patients with AS and 301 healthy control subjects.
RESULTS: Seventeen SNPs located within or near the HLA-DPA1 and HLA-DPB1 loci showed association with AS (P = 1.38 × 10⁻⁵ to 0.05). In addition, multimarker tests, both linkage disequilibrium and sliding windows, showed association of some groups of adjacent SNPs within the HLA-DPA1/DPB1 region with AS (P = 1.0 × 10⁻⁴ to 3.96 × 10⁻⁷). We validated the association by genotyping 5 SNPs from the DPA1/DPB1 region in an additional cohort and obtained P values from 6.42 × 10⁻⁵ to 0.01 in the analysis of the combined cohorts. Subtyping analysis of HLA-DPA1 and HLA-DPB1 showed that HLA-DPA1*01:03, A1*02:01, and B1*13:01 were the subtypes most susceptible to AS.
CONCLUSION: HLA markers and linkage disequilibrium blocks near HLA-DPA1 and HLA-DPB1 are statistically associated with AS. We identified a region located around the HLA-DPA1 and HLA-DPB1 loci associated with AS, another region within the MHC that is different from HLA-B27.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769851     DOI: 10.1002/art.30555

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  6 in total

Review 1.  Revisiting MHC genes in spondyloarthritis.

Authors:  Maxime Breban; Félicie Costantino; Claudine André; Gilles Chiocchia; Henri-Jean Garchon
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

Review 2.  An update on the contribution of the MHC to AS susceptibility.

Authors:  John D Reveille
Journal:  Clin Rheumatol       Date:  2014-05-18       Impact factor: 2.980

3.  Predicting the potential ankylosing spondylitis-related genes utilizing bioinformatics approaches.

Authors:  Hao Zhao; Dan Wang; Deyu Fu; Luan Xue
Journal:  Rheumatol Int       Date:  2014-11-29       Impact factor: 2.631

4.  HLA class I and II alleles in susceptibility to ankylosing spondylitis.

Authors:  John D Reveille; Xiaodong Zhou; MinJae Lee; Michael H Weisman; Lin Yi; Lianne S Gensler; Hejian Zou; Michael M Ward; Mariko L Ishimori; Thomas J Learch; Dongyi He; Mohammad H Rahbar; Jiucun Wang; Matthew A Brown
Journal:  Ann Rheum Dis       Date:  2018-10-19       Impact factor: 19.103

5.  A Single Nucleotide Polymorphism in the Il17ra Promoter Is Associated with Functional Severity of Ankylosing Spondylitis.

Authors:  Jose Ramón Vidal-Castiñeira; Antonio López-Vázquez; Roberto Diaz-Peña; Paula Diaz-Bulnes; Pablo Martinez-Camblor; Eliecer Coto; Pablo Coto-Segura; Jacome Bruges-Armas; Jose Antonio Pinto; Francisco Jose Blanco; Alejandra Sánchez; Juan Mulero; Ruben Queiro; Carlos Lopez-Larrea
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

6.  An HLA-C amino-acid variant in addition to HLA-B*27 confers risk for ankylosing spondylitis in the Korean population.

Authors:  Kwangwoo Kim; So-Young Bang; Seunghun Lee; Hye-Soon Lee; Seung-Cheol Shim; Young Mo Kang; Chang-Hee Suh; Celi Sun; Swapan K Nath; Sang-Cheol Bae; Tae-Hwan Kim
Journal:  Arthritis Res Ther       Date:  2015-11-27       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.